Miracle Mile Advisors LLC Makes New $27,000 Investment in ChromaDex Co. (NASDAQ:CDXC)

Miracle Mile Advisors LLC bought a new position in shares of ChromaDex Co. (NASDAQ:CDXC) during the 2nd quarter, Holdings Channel.com reports. The firm bought 10,000 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds have also recently bought and sold shares of CDXC. Lazard Asset Management LLC acquired a new stake in shares of ChromaDex in the first quarter valued at about $43,000. SG Americas Securities LLC acquired a new stake in ChromaDex during the first quarter worth about $54,000. Acadian Asset Management LLC acquired a new stake in ChromaDex during the first quarter worth about $67,000. Perritt Capital Management Inc. acquired a new stake in ChromaDex during the first quarter worth about $139,000. Finally, International Assets Investment Management LLC grew its position in ChromaDex by 43.0% during the fourth quarter. International Assets Investment Management LLC now owns 28,600 shares of the company’s stock worth $410,000 after buying an additional 8,600 shares in the last quarter. 15.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CDXC shares. Roth Mkm reissued a “buy” rating and set a $6.00 target price on shares of ChromaDex in a research report on Wednesday, June 12th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of ChromaDex in a research report on Friday, August 9th.

ChromaDex Stock Up 1.4 %

CDXC traded up $0.04 during midday trading on Friday, reaching $3.34. 309,204 shares of the company’s stock were exchanged, compared to its average volume of 309,625. The firm has a market capitalization of $252.30 million, a price-to-earnings ratio of -66.80 and a beta of 1.87. ChromaDex Co. has a one year low of $1.25 and a one year high of $4.65. The business has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $2.82.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.